Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) has announced the appointments of Dr. Prasanth Reddy as senior vice president and enterprise oncology head, and Dr. Robert Phillips as vice president and head of enterprise oncology science. This move aims to strengthen Labcorp's capabilities in cancer diagnosis, treatment, and drug development. Dr. Reddy and Dr. Phillips bring extensive experience in oncology and drug-linked diagnostics from their previous positions at Foundation Medicine and Daiichi-Sankyo, respectively. Labcorp continues to expand its leadership in advancing innovative cancer solutions.
Summary not available.
Labcorp (NYSE: LH) has appointed Dr. Deborah Ann Sesok-Pizzini as its new Chief Medical Officer of Labcorp Diagnostics, effective January 11, 2021, following Dr. Dot Adcock's retirement in April 2021. Dr. Sesok-Pizzini brings over 20 years of healthcare experience, having previously served in various leadership roles at The Children's Hospital of Philadelphia and as a professor at the University of Pennsylvania. Dr. Brian Caveney expressed enthusiasm about her contributions to the team.
Labcorp (NYSE: LH) will announce its fourth quarter and full year 2020 financial results on Feb. 11, 2021, prior to market opening. A conference call will follow at 9:00 a.m. ET to discuss the results. Last year, Labcorp reported revenues of $11.5 billion. The investor relations website will provide the earnings release and additional information. An audio replay of the call will be available until Feb. 25, 2021. The company advises stakeholders to consider forward-looking statements cautiously due to various market risks.
Labcorp (NYSE: LH) has secured a contract with the CDC to conduct genomic sequencing for SARS-CoV-2, supporting a comprehensive genomic survey across the U.S. The initiative aims to enhance national surveillance, identify new variants, and refine public health responses. Labcorp will process random de-identified samples that test positive for the virus, contributing to the CDC's goal of increasing genomic sequencing capacity. This collaboration is set to double the weekly genomic sample sequencing rate, as stated by Labcorp's Chief Scientific Officer, Dr. Marcia Eisenberg.
Labcorp (NYSE: LH) announced that Dr. Brian Caveney, chief medical officer, was recognized by Modern Healthcare as one of the 100 most influential people in healthcare for 2020. This accolade highlights Dr. Caveney's leadership during the COVID-19 pandemic, including the launch of the first commercial COVID-19 PCR test. He praised Labcorp's teams for their dedication and innovation in addressing the crisis. The full ranking is available in the December issue of Modern Healthcare. Labcorp reported $11.5 billion in revenue for FY2019, providing critical insights to improve health worldwide.
Labcorp (NYSE: LH) announced participation in a virtual fireside chat at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 8:20 a.m. (EST). The event will provide insights from the executive management team and will be available via live webcast on their website. With reported revenue of $11.5 billion in FY2019, Labcorp continues to leverage its diagnostics and drug development capabilities across over 100 countries, aiming to enhance healthcare decisions globally.
Labcorp (NYSE: LH) announced that its Pixel by Labcorp™ At-Home COVID-19 Collection Kit is now available through Walgreens Find Care®. This digital health platform assists users in accessing COVID-19 testing services easily. Patients can initiate testing by completing a survey, and kits are shipped for self-collection, with results available online. Labcorp aims to provide convenient health services and enhance access to testing amid the COVID-19 pandemic, which is crucial for informed health decisions.
LabCorp (NYSE: LH) has received FDA Emergency Use Authorization for the Pixel by LabCorp COVID-19 Test Home Collection Kit, marking it as the first over-the-counter kit without a prescription requirement. This enables broad distribution through retail channels, enhancing access to COVID-19 testing. The kit allows self-collection in a private setting, minimizing virus transmission, and results are securely delivered via the Pixel portal. LabCorp aims to empower users to make informed health decisions and reduce the spread of COVID-19.
LabCorp (NYSE: LH) will participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 3 at 1:50 p.m. ET. The discussion will be streamed live on the company's website and will also be available for replay. LabCorp is an S&P 500 company dedicated to advancing health and patient care. In 2019, the company reported revenues of over $11.5 billion, providing extensive clinical laboratory and drug development services. For further information, visit www.LabCorp.com.